TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Total Current Liabilities
All obligations due within one year.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities broadly unchanged from a year ago
Total current liabilities stood at $11.79M at the end of Q1 FY2026, up 0.3% from a year earlier and up 2.5% from the prior quarter. Over 3 fiscal years it compounded at -29.2% a year.
Context
- Total current liabilities amounted to 16.6% of total assets at the end of Q1 FY2026, down 24.5 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +0.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 11.5M USD
- Year-over-year change
- +12.4%
- 4-year CAGR
- +15.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.5M | +12.4% |
| FY2024 | 2024-12-31 | 10.23M | -30.4% |
| FY2023 | 2023-12-31 | 14.69M | -54.6% |
| FY2022 | 2022-12-31 | 32.36M | +407.7% |
| FY2021 | 2021-12-31 | 6.37M | — |
Total Current Liabilities vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's Mar 2026 total current liabilities of $11.79M is the 8th highest of the 11 companies compared; the peer median is $17.34M.
- Its year-over-year change of +0.3% is the 6th highest of 11, against a peer median of +4.4%.
- Total current liabilities amounts to 16.6% of total assets for TLSI, versus a peer median of 13.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $48.14M | +18.3% | -12.8% | 55.5% | |
| Mar 2026 | $31.49M | +148.3% | +120.5% | 7.7% | |
| Mar 2026 | $28.29M | +13.9% | -2.8% | 22.5% | |
| Mar 2026 | $25.64M | -32.0% | -21.5% | 14.6% | |
| Mar 2026 | $17.8M | -34.5% | +52.6% | 26.9% | |
| Dec 2025 | $16.89M | +20.9% | -12.3% | 10.4% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $13.69M | -5.1% | +52.3% | 4.6% |
| Mar 2026 | $11.79M | +0.3% | -29.2% | 16.6% | |
| Mar 2026 | $10.64M | +101.0% | +25.7% | 14.4% | |
| Mar 2026 | $10.21M | -19.8% | -2.6% | 5.3% | |
| Mar 2026 | $9.23M | -91.7% | -28.9% | 13.2% | |
| Peer median (excluding TLSI) | $17.34M | +4.4% | -2.7% | 13.8% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.3M | 9.41M | 11.78M | 8.53M | 20.44M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.36M | 1.56M | 3.55M | 5.09M | 6.56M |
| Inventory | 1.29M | 1.47M | 2.55M | 4.05M | 3.08M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 35.13M | 17.21M | 20.86M | 20.67M | 32.24M |
| Property, Plant & Equipment (Net) | 1.8M | 3.61M | 3.27M | 2.88M | 2.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 794K | 802K | 0 | 0 | 0 |
| Long-term Investments | 0 | 250K | 0 | 350K | 400K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 115K | 117K | 466K | 73K | 18K |
| Total Non-current Assets | 2.71M | 4.78M | 3.74M | 3.3M | 3.09M |
| Total Assets | 37.84M | 22M | 24.6M | 23.97M | 35.33M |
| Account Payables | 1.3M | 4.95M | 3.39M | 2.27M | 3M |
| Short-term Debt | 0 | 370K | 0 | 0 | 167K |
| Tax Payables | 0 | 0 | 0 | 34K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 104K | 23.57M | 420K | 383K | 8.23M |
| Total Current Liabilities | 6.37M | 32.36M | 14.69M | 10.23M | 11.5M |
| Long-term Debt | 0 | 0 | 0 | 22.08M | 34.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 561K | 369K | 35.73M | 16.22M | 23.42M |
| Total Non-current Liabilities | 561K | 1.96M | 36.98M | 39.64M | 57.69M |
| Total Liabilities | 6.93M | 34.32M | 51.66M | 49.87M | 69.19M |
| Common Stock | 11K | 0 | 2K | 3K | 4K |
| Retained Earnings | (136.34M) | (186.36M) | (249.5M) | (279.55M) | (330.58M) |
| Accumulated OCI | 0 | 0 | (0) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 30.9M | (12.32M) | (27.07M) | (25.89M) | (33.86M) |
| Total Debt | 0 | 1.96M | 1.6M | 23.63M | 34.44M |
| Net Debt | (30.3M) | (7.45M) | (10.18M) | 15.1M | 14M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.